Patent classifications
C07F9/6518
Application of click chemistry for signal amplification in IHC and ISH assays
Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes click chemistry to covalently bind reporter molecules to tissue.
SMALL MOLECULE COMPOUNDS WITH PHOSPHORYLATED ARYL STRUCTURES AND USE THEREOF
The present application discloses a small molecule compound having a phosphorylated aromatic structure and application thereof. The compound and pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof provided in the present application or the pharmaceutical composition provided in the second aspect of the present invention, by targeting the TEAD palmitoyl pocket, effectively inhibits/blocks YAP-TEAD binding, inhibits/blocks the transcription function of YAP-TEAD, thereby preventing and/or treating diseases related to increased TEAD transcription levels and/or YAP phosphorylation disorders and/or Hippo signaling pathway disorders.
SMALL MOLECULE COMPOUNDS WITH PHOSPHORYLATED ARYL STRUCTURES AND USE THEREOF
The present application discloses a small molecule compound having a phosphorylated aromatic structure and application thereof. The compound and pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof provided in the present application or the pharmaceutical composition provided in the second aspect of the present invention, by targeting the TEAD palmitoyl pocket, effectively inhibits/blocks YAP-TEAD binding, inhibits/blocks the transcription function of YAP-TEAD, thereby preventing and/or treating diseases related to increased TEAD transcription levels and/or YAP phosphorylation disorders and/or Hippo signaling pathway disorders.
NOVEL COMPOUND AS FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
The present invention relates to a novel compound acting as a functional antagonist for S1PR1 and S1PR4, and a use thereof. The compound according to the present invention exhibits significantly excellent binding strength to S1PR1 and S1PR4 receptors, thus exhibiting an excellent effect in preventing or treating inflammatory bowel disease, alopecia areata (AA), or an autoimmune disease.
NOVEL COMPOUND AS FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
The present invention relates to a novel compound acting as a functional antagonist for S1PR1 and S1PR4, and a use thereof. The compound according to the present invention exhibits significantly excellent binding strength to S1PR1 and S1PR4 receptors, thus exhibiting an excellent effect in preventing or treating inflammatory bowel disease, alopecia areata (AA), or an autoimmune disease.